[Market Focus] LaserOptek Rises on Anticipation for World's First Solid-State Laser, Eyes "10-Year Growth Engine" and U.S. FDA Approval

Shares of LaserOptek, a company specializing in laser devices, are rising. Expectations for improved performance in the second half of this year, driven by the launch of new products and expansion into overseas markets, appear to be influencing the stock price.

As of 9:54 a.m. on September 2, LaserOptek was trading at 7,250 won, up 4.47% from the previous trading day.

LaserOptek expects the impact of its new products to become more pronounced in the second half of this year. The company has launched the "Sculpio," a device for skin elasticity and contour lifting, as well as the world's first 250-millijoule high-powered 785-nanometer picolaser, "New Helios785 Pico," both of which are generating strong market responses. The new Helios product increases output by 25% compared to previous models, reducing the number of procedures required and delivering faster clinical results. The company also anticipates increased sales of consumables to further boost revenue.

LaserOptek is also preparing to launch the "Vascura589," a vascular treatment device. This is the world's first solid-state laser system specialized for treating vascular lesions such as hemangiomas and port-wine stains. The device is currently undergoing electromagnetic and electrical safety testing, and the approval process with the Ministry of Food and Drug Safety is in its final stages.

LaserOptek plans to submit the technical documents for Vascura589's product approval to the Ministry of Food and Drug Safety within this month. The company aims to complete product approval as early as within this year. Typically, it takes about three months from document submission to product approval, although the timeline may be extended depending on whether supplementary materials are required. The company is planning to launch the product domestically in the first half of next year and is also preparing to obtain FDA approval for entry into the U.S. market. LaserOptek views this product as a "10-year growth engine" that will drive its mid- to long-term growth.

According to market research firm Allied Market Research, the target market for Vascura589 is expected to grow from 17 trillion won in 2020 to 35 trillion won by 2030. This projection covers the global skin clinic market, including both treatments and procedures.

Vascura589 is the world's first vascular treatment device to utilize a Raman laser. The Raman laser is a technology that applies the "Raman effect," discovered by Nobel Prize-winning Indian physicist Raman, to lasers. The device is expected to offer groundbreaking treatment for vascular lesions such as rosacea (strawberry nose), facial flushing, and spider veins.